	US 11,925,621 B2
	Medicinal preparation for external use
Masayasu Tanaka, Suita (JP); Yoshihiro Oyamada, Suita (JP); and Yoshinori Takada, Osaka (JP)
Assigned to SUMITOMO PHARMA CO., LTD., Osaka (JP)
Appl. No. 17/260,123
Filed by Sumitomo Pharma Co., Ltd., Osaka (JP)
PCT Filed Jul. 18, 2019, PCT No. PCT/JP2019/028251 § 371(c)(1), (2) Date Jan. 13, 2021, PCT Pub. No. WO2020/017585, PCT Pub. Date Jan. 23, 2020.
Claims priority of application No. 2018-136147 (JP), filed on Jul. 19, 2018.
Prior Publication US 2021/0322385 A1, Oct. 21, 2021
Int. Cl. A61K 31/4184 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61P 29/02 (2006.01)

CPC A61K 31/4184 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61P 29/02 (2018.01)]

13 Claims

1. A pharmaceutical composition for external use comprising N²-{[1-ethyl-6-(4-methylphenoxy)-1H-benzimidazol-2-yl]methyl}-L-alaninamide or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the composition is substantially free from water.